Scheller Richard H's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Aug 6, 2021
- Accession no.
- 0000899243-21-031954
- Filed
- Aug 6, 2021
- Trade date
- Aug 4, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $733.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scheller Richard HCIK 0001214133 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2021 | Common Stock | MOption exerciseAcquired | +13,777 | $17.00 | +$234,209 | 59,637 | Direct | |
| Aug 4, 2021 | Common Stock | SSaleDisposed | −13,777 | $53.23F1 | −$733,349.71 | 45,860 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2021 | Common Stock | MOption exerciseDisposed | −13,777 | $0.00 | $0 | 39,611 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average sale price of the shares sold from $52.839 to $53.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Title: Chairman of Research and Development